Mingbao Zhang

USPTO Granted Patents = 25 (Patent Applications = 12)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 4

Average Co-Inventor Count = 2.7

ph-index = 9

Forward Citations = 262(Granted Patents)

Location History:

Stamford, CT (US) (2004 - 2021)
Millwood, NY (US) (2013 - 2022)

Company Filing History:

12 out of 24

Marinus Pharmaceuticals

patents

5 out of 70

Bayer Pharmaceuticals Corporation

Insignis Therapeutics, Inc.

6. 1 out of 832,680

Other

patents

Years Active: 2004-2022

Loading Chart...

25 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11213496 - Methods of using dipivefrin (2022-01-04),

2. 11213484 - Dipivefrin orally disintegrating tablet formulations (2022-01-04),

3. 11071740 - Method of treatment using nanoparticulate ganaxolone formulations (2021-07-27),

4. 10780099 - Injectable neurosteroid formulations containing nanoparticles (2020-09-22),

5. 9452176 - Solid ganaxolone compositions and methods for the making and use thereof (2016-09-27),

6. 9056116 - Liquid ganaxolone formulations and methods for the making and use thereof (2015-06-16),

7. 9029355 - Solid ganaxolone compositions and methods for the making and use thereof (2015-05-12),

8. 9017728 - Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof (2015-04-28),

9. 8618087 - Solid ganaxolone formulations and methods for the making and use thereof (2013-12-31),

10. 8552203 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation (2013-10-08),

11. 8541618 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation (2013-09-24),

12. 8455002 - Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof (2013-06-04),

13. 8367651 - Solid ganaxolone formulations and methods for the making and use thereof (2013-02-05),

14. 8362028 - Pseudobase benzo[c]phenanthridines with improved efficacy, stability and safety (2013-01-29),

15. 8318714 - Liquid ganaxolone formulations and methods for the making and use thereof (2012-11-27),

Title: **Mingbao Zhang: A Pioneer in Innovative Pharmaceutical Formulations**

Introduction

Mingbao Zhang, based in Stamford, CT, is a prominent inventor with a significant contribution to the pharmaceutical field. With an impressive portfolio of 25 patents, Zhang has made notable advancements in drug formulation, particularly in delivering epinephrine and its derivatives.

Latest Patents

Among his latest innovations are the orally disintegrating dipivefrin tablet formulations, which offer a rapid method for delivering epinephrine to patients. These formulations are designed with a blend of binders, matrix formers, and taste masking agents to ensure efficacy and patient compliance. Furthermore, his patent also details methods for the systemic delivery of epinephrine, especially tailored for conditions such as asthma, allergic reactions, and even certain cancers. The ease of administration via orally dissolving tablets represents a significant advancement in treatment options for these serious health issues.

Career Highlights

Mingbao Zhang's professional journey includes pivotal roles at renowned companies like Marinus Pharmaceuticals and Bayer Pharmaceuticals Corporation. His expertise in pharmaceutical sciences has allowed him to develop innovative solutions aimed at improving patient outcomes through advanced drug delivery technologies.

Collaborations

Throughout his career, Zhang has collaborated with esteemed professionals including Kenneth Shaw and Derek B. Lowe. These partnerships have facilitated the development of groundbreaking pharmaceutical solutions, further enhancing the impact of his inventions within the industry.

Conclusion

Mingbao Zhang stands out as a leading innovator in the pharmaceutical sector with his impressive array of patents and contributions to drug formulation. As he continues to push the boundaries of medicinal science, his work promises to significantly benefit patients requiring effective and efficient treatment options.

This text is generated by artificial intelligence and may not be accurate.